OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Functional Landscape of SARS-CoV-2 3CL Protease
Sho Iketani, Seo Jung Hong, Jenny Sheng, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 6
Sho Iketani, Seo Jung Hong, Jenny Sheng, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 6
Showing 6 citing articles:
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Sho Iketani, Hiroshi Mohri, Bruce Culbertson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 43
Sho Iketani, Hiroshi Mohri, Bruce Culbertson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 43
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
Daniele Focosi, Scott A. McConnell, Shmuel Shoham, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 2, pp. 106708-106708
Open Access | Times Cited: 31
Daniele Focosi, Scott A. McConnell, Shmuel Shoham, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 2, pp. 106708-106708
Open Access | Times Cited: 31
The impact of SARS-CoV-2 3CL protease mutations on nirmatrelvir inhibitory efficiency. Computational insights into potential resistance mechanisms
Carlos A. Ramos‐Guzmán, Milorad Andjelkovic, Kirill Zinovjev, et al.
Chemical Science (2023) Vol. 14, Iss. 10, pp. 2686-2697
Open Access | Times Cited: 21
Carlos A. Ramos‐Guzmán, Milorad Andjelkovic, Kirill Zinovjev, et al.
Chemical Science (2023) Vol. 14, Iss. 10, pp. 2686-2697
Open Access | Times Cited: 21
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Large library docking for novel SARS‐CoV ‐2 main protease non‐covalent and covalent inhibitors
Elissa A. Fink, Conner Bardine, Stefan Gahbauer, et al.
Protein Science (2023) Vol. 32, Iss. 8
Open Access | Times Cited: 20
Elissa A. Fink, Conner Bardine, Stefan Gahbauer, et al.
Protein Science (2023) Vol. 32, Iss. 8
Open Access | Times Cited: 20
Impact of SARS-CoV-2 3CL Protease Mutations on Nirmatrelvir Inhibitory Efficiency. Computational Insights into Potential Resistance Mechanisms
Carlos A. Ramos‐Guzmán, Milorad Andjelkovic, Kirill Zinovjev, et al.
(2022)
Open Access
Carlos A. Ramos‐Guzmán, Milorad Andjelkovic, Kirill Zinovjev, et al.
(2022)
Open Access
